Rabbit Anti-Human CD353/SLAMF8 Monoclonal Antibody for Flow Cytometry - Q9P0V8

Core Product Specifications and Parameters

Biological Background: SLAMF8 Function and Localization

• SLAM family member 8 (SLAMF8), also known as B-lymphocyte activator macrophage expressed (BLAME) or CD353, is a single-pass type I transmembrane protein belonging to the signaling lymphocyte activation molecule (SLAM) family within the immunoglobulin superfamily.
• It contains an extracellular Ig-like domain and is predicted to be involved in immune cell signaling, particularly in B-cell lineage commitment and modulation of signaling through the B-cell receptor.
• SLAMF8 is expressed in lymphoid tissues, including lymph node, spleen, thymus, and bone marrow, suggesting a role in B-cell development and homeostasis.
• The protein is predicted to undergo post-translational modifications such as N-linked glycosylation and disulfide bond formation, which may influence its structure and function on the cell surface.
• Alternative splicing produces multiple transcript variants encoding different isoforms.

Experimental Guidance and Technical Tips

• For flow cytometry, this -conjugated antibody can be used directly; optimal titers should be determined empirically for each sample type.
• Validate specificity using positive controls such as human lymph node mononuclear cells or tissues known to express SLAMF8, and include isotype controls to assess background staining.
• Due to the fluorophore (similar to FITC), ensure proper compensation in multicolor flow cytometry panels, especially when used alongside PE or other fluorophores with overlapping emission spectra.
• The immunogen covers the extracellular domain (aa 23–123), making this clone suitable for surface staining of native antigen; verify performance in intracellular staining if required.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. For B-cell and immune research applications, we offer validated monoclonal antibodies like this anti-CD353/SLAMF8 clone, along with optimized antibody pairs, bulk ancillary reagents, and rare-target raw-material sourcing. Explore our portfolio to accelerate your diagnostic development.